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A B S T R A C T
BACKGROUND AND PURPOSE: The objective of this study was to longitudinally investigate the trajectory of change in 1H
MRS measurements in asymptomatic MAPT mutation carriers who became symptomatic during follow-up, and to determine the
time at which the neurochemical alterations accelerated during disease progression.
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METHODS: We identified eight MAPT mutations carriers who transitioned from asymptomatic to symptomatic disease during
follow-up. All participants were longitudinally followed with an average of 7.75 years (range 4-11 years) and underwent two
or more single voxel 1H MRS examinations from the posterior cingulate voxel, with a total of 60 examinations. The rate of
longitudinal change for each metabolite was estimated using linear mixed models. A flex point model was used to estimate the
flex time point of the change in slope.
RESULTS: The decrease in the NAA/mI ratio accelerated 2.09 years prior to symptom onset, and continued to decline. A similar
trajectory was observed in the presumed glial marker mI/Cr ratio accelerating 1.86 years prior to symptom onset.
CONCLUSIONS: Our findings support the potential use of longitudinal 1H MRS for monitoring the neurodegenerative progres-
sion in MAPT mutation carriers starting from the asymptomatic stage.
Introduction
Frontotemporal lobar degeneration is a neurodegenerative
disorder with heterogeneous clinical features, characterized
by behavioral and language disorders, impaired social and
executive dysfunction, and some patients also develop features
of motor neuron disease, progressive supranuclear palsy, and
cortical basal syndrome. It is highly heritable with an autosomal
dominant family history in about 30-50% FTLD patients,1
usually associated with mutations of microtubule-associated
protein tau (MAPT) gene.2 Families with MAPT mutations
provide an opportunity to identify biomarkers for early
neurodegenerative changes and tracking disease progression
starting from asymptomatic stage.
Proton magnetic resonance spectroscopy (1H MRS) pro-
vides quantitative in vivo assessment of several brain metabo-
lites in a single scan that are associated with early neurodegen-
erative pathology. 1H MRS measurements from the posterior
cingulate gyrus have identified neurochemical abnormalities
in both asymptomatic and symptomatic carriers of MAPT
mutation.3 A decrease in the neuronal integrity marker N-
acetylaspartate (NAA) or NAA to creatine (NAA/Cr) and eleva-
tion in possible glial marker myoinositol (mI) or mI to creatine
(mI/Cr) have been found in symptomatic patients with FTLD,4
while only elevation in mI/Cr has been found in asymptomatic
MAPT mutation carriers in the posterior cingulate gyrus.3
Longitudinal 1HMRS studies inAlzheimer’s disease demon-
strated longitudinal decline in the neuronal integrity marker
NAAand elevation inmI,5–7 suggesting serialMRS is a potential
biomarker for following the progression of neurodegenerative
diseases. Establishing the trajectory of biomarker changes
preceding the clinical disease onset during the asymptomatic
stage in MAPT mutation carriers is crucial for assessing the
effects of potential therapies that are currently being developed.
The objectives of this study were: (1) to longitudinally in-
vestigate the trajectory of change in 1H MRS measurements in
MAPTmutations carriers who converted from asymptomatic to
symptomatic status; and (2) to determine the time at which the
neurochemical changes accelerated during disease progression.
Methods
Participants
Participants in this study were recruited from the Mayo
Clinic Alzheimer’s Disease Research Center (ADRC) and the
Longitudinal Evaluation of Familial Frontotemporal Dementia
Subjects (LEFFTDS) studies at the Mayo Clinic site between
August 2006 to July 2017. LEFFTDS is a multisite study inves-
tigating the biomarkers of disease progression in familial FTLD
mutation carriers. The current study included participants who
screened positive for a mutation in MAPT with no clinical
symptoms at baseline, but transitioned from asymptomatic to
symptomatic disease during follow-up, which we refer to as
converters (n = 8; 4 females; median age = 41.5). Converters
were from four individual families with MAPT mutations (four
with N279K, two with V337M, one with P301L, and one with
IVS9-10G>Tmutations) with a mean score 29.75 (range 29-30)
on the Mini-Mental State Examination (MMSE) at the baseline
evaluation. All participants were followed prospectively with
annual clinical examination at the time of MRI/1H MRS
examination, including a medical history review, mental status
examination, a neurological examination by a clinician with
FTLD expertise and a neuropsychological examination.
None of the participants had structural lesions that could
cause cognitive impairment or dementia, such as cortical infarc-
tion, subdural hematoma, or tumor, or had concurrent illness
that would interfere with cognitive function other than FTLD
on baseline and follow-up examinations.
All participants have undergone genetic testing for research
and the behavioral neurologists evaluating the participants were
blinded to the findings of the genetic testing for research be-
fore the phenoconversion. Informed consent was obtained from
all participants for participation in the studies, which were ap-
proved by the Mayo Institutional Review Board.
MRS and MRI
Single voxel (SV) 1H MRS studies were performed at 3T us-
ing an eight-channel phased array head coil (GE Healthcare,
Milwaukee, WI). A 3-dimensional high-resolution T1-weighted
magnetization-prepared rapid gradient echo (MPRAGE) acqui-
sition with repetition time/echo time/inversion time = 7/3/900
milliseconds, flip angle 8 degrees, in-plane resolution of 1.0mm,
and a slice thickness of 1.2 mm was performed in sagittal plane
for voxel positioning. 1H MRS studies were performed using
the automated MRS package (PROBE/SV; GE Healthcare).
Point resolved spectroscopy sequence with repetition time =
2,000 milliseconds, echo time = 30 milliseconds, 2,048 data
points, and 128 excitation was used for the examination.
An 8 cm3 (2 × 2 × 2 cm) voxel was placed by trained MRI
technologists on a mid-sagittal T1 weighted image, included
right and left posterior cingulate gyri and inferior precunei.
The anterior border of splenium, the superior border of corpus
callosum and the cingulate sulcus were the anatomical land-
marks to define the anterior inferior and the anterior superior
border of the voxel. Individual voxel placements were visually
evaluated by a trained image analyst for quality control. 1HMR
spectra from voxels that were not properly placed according to
predetermined anatomic landmarks, those with low signal-to-
noise ratio (SNR), poor water suppression, lipid contamination,
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wide line widths or baseline distortions failed the quality con-
trol and were excluded. In this study, none of the spectra had
to be excluded due to poor quality.
The PROBE’s prescan algorithm automatically adjusts the
transmitter and receiver gains and center frequency. The local
magnetic field homogeneity is optimized with the 3-plane auto-
shim procedure and the flip angle of the third water suppression
pulse is adjusted for chemical shift water suppression (CHESS)
prior to point-resolved spectroscopy acquisition. Metabolite in-
tensity ratios are automatically calculated using a previously
validated algorithm at the end of each PROBE/SV.8,9 1H MRS
metabolite ratios that were analyzed for this study included N-
acetylaspartate/Creatine (NAA/Cr), myo-inositol (mI)/Cr, and
NAA/mI based on previous cross-sectional studies in MAPT
mutation carriers showing abnormalities in these metabolite
ratios.3
Genetic Analysis
Analysis of MAPT exons 1, 7, and 9-13 was performed using
primers and conditions that were previously published.10 PCR
amplicons were purified using the Multiscreen system (Mil-
lipore, Billerica, MA) and then sequenced in both directions
using Big Dye chemistry following the manufacturer’s protocol
(Applied Biosystems, Froster City, CA). Sequence products
were purified using the Montage system (Millipore) before
being run on an Applied Biosystem 3730 DNA Analyzer.
Sequence data were analyzed using either SeqScape (Applied
Biosystem) or Sequencher software (Gene Codes, Ann Arbor,
MI).
Statistical Analysis
Baseline characteristics of converters with MAPT mutations
were described with means, standard deviations, counts and
proportions. We modeled the annual percent change of
NAA/Cr, NAA/mI, and mI/Cr ratios using linear mixed ef-
fects models with a flex point in the fixed effects. The flex point
models allow the regression slopes to change at some time be-
fore, at, or after the time of conversion. The models thus have
two estimated regression lines, one with the first slope in the
early times and one with the second slope at later times, with
their point of intersection being the flex point. This flex point
was estimated in the models using a dummy variable to shift the
estimated line with the second slope up or down, thereby mov-
ing the flex point left or right. The specific coding in our models
estimated a slope over the entire time, and then a modifier to
the slope after the flex point. If the flex point was not signifi-
cantly different from the time of conversion, we reduced to a
more parsimonious model with slope change at the time of con-
version. If in addition the slopes before and after the flex point
did not differ, we reduced to a model with a single slope over
the time span. We used P values, Akaike Information Criterion
(AIC), and Bayesian Information Criterion (BIC) to evaluate
the models. The mixed models used random intercepts to ac-
count for within-subject repeated measures correlations nested
in within-family correlations. This allowed for dependence in
the repeated measures per subject, and also dependence in fam-
ily members. Families were assumed to be independent from
each other. Because of the sample size restrictions, we were only
able to use random intercepts in these models. Inclusion of ran-
dom slopes and flex points would result in gross overfitting of
the models, and nonconvergence.
Table 1. Participant Characteristics at Baseline
MAPT Mutation Carriers
Female, number (%) 4 (50.0%)
Education, year 15 (1)
Age at MRI scan, year 41 (6)
MMSE 30 (.46)
NPI total 1 (1)
DRS total MOANS 12 (2)
AVLT delay recalled MOANS 12 (3)
NAA/Cr ratio 1.67 (.06)
mI/Cr ratio 0.54 (.04)
NAA/mI ratio 3.11 (.3)
Data shown are number (%) or mean (standard deviation).
MRI = magnetic resonance image; MMSE = Mini-Mental State Examinations;
NPI = Neuropsychiatric Inventory; DRS = Dementia rating scale; MOANS =
Mayo’s Older Americans Normative Studies; AVLT = Auditory-verbal learning
test; NAA = N-acetylaspartate; Cr = creatine; mI = myoinositol.
Results
Table 1 describes the baseline characteristics of the converters.
The converters were followed for a median of 8.2 years (range
3.8 to 10.7 years) and had at least two 1H MRS scans from the
posterior cingulate gyrus, with a total of 60 1H MRS examina-
tions included in eight participants. 1H MRS acquisitions from
the posterior cingulate voxel past the quality control assessment
and were successful for the quantification of metabolite ratios
in all participants.
The median age of symptom onset was 45.5 years with a
range of 36-58 years. At the time of conversion, all participants
were classified as mild cognitive impairment (MCI), with two
later developing behavioral variant frontotemporal dementia
(bvFTD), two developing mixed bvFTD and PSP (Richard-
son’s syndrome), one developing bvFTD with Parkinsonism,
and three remaining as MCI.
The flex point model demonstrated a change in slope
in mI/Cr ratios (P = .008) and NAA/mI ratios (P = .005;
Fig 1). Representative longitudinal spectra from a converter
withMAPTmutation are shown in Figure 2. The increase in the
presumed glial marker mI/Cr ratio accelerated 1.86 years prior
to symptom onset, and continued to increase with the slope
of .04 per year after the flex point (CI: .01, .07, P = .008). A
similar trajectory of decrease in the NAA/mI ratio accelerated
2.09 years prior to symptom onset, and continued to decline
with a slope of -.30 per year (CI: -.50, -.10, P = .005). No evi-
dence of longitudinal change was observed in NAA/Cr during
the follow-up period (Table 2).
Discussion
In current study, we report the trajectory of serial 1H MRS
metabolite ratio changes from the posterior cingulate voxel in
MAPTmutation carriers who converted from the asymptomatic
to symptomatic disease during the longitudinal study. Findings
were characterized by a trajectory of increasing mI/Cr and
decreasing NAA/mI ratios that begin approximately 2 years
prior to symptom onset. Our study extends upon prior cross-
sectional findings of elevated mI/Cr and decreased NAA/mI
in asymptomatic MAPT mutation carriers.3
One of the key findings in our study is the accelerated
changes in mI/Cr and NAA/mI that occurred in approximately
2 years prior to symptom onset, suggesting a change in the
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Fig 1. The flex point model for 1H MRS metabolite ratios. In the x axis, 0 indicates the actual age of symptom onset for converters with MAPT
mutation. The metabolite ratios are in the y axis. The black line shows the predicted values calculated from the flex-point models. NAA/Cr ratios
did not have a “flex-point” during the follow-up time window (A). The increase of the presumed glial marker mI/Cr accelerated in 1.86 years
prior to symptom onset, and continued to increase in time (B). A similar trajectory of decrease was observed the neuronal marker NAA/mI ratio
2.09 years prior to symptom onset (C). NAA = N-acetylaspartate; Cr = creatine; mI = myo-inositol.
trajectory of 1HMRSmetabolite ratios prior to symptom onset.
Our findings are consistent with the trajectories reported in a re-
cent longitudinal study of converters withMAPT andGRNmuta-
tions, demonstrating that loss of white matter integrity and grey
matter volume were present 2 years before symptom onset.11
In addition, previous cross-sectional studies in asymptomatic
MAPT mutation carriers report presence of 1H MRS metabo-
lite ratio abnormalities,3 grey matter atrophy,12 loss of white
matter integrity,13 and functional connectivity14 with range of
5 to 30 years before the estimated age of symptom onset. It
should be noted that the cross-sectional studies estimated the
age of onset by the information available from the carriers of
the MAPT mutation type. Heterogeneity in symptom onset is a
common feature across different mutations and within individ-
uals from the same family. On the other hand, in the current
study we were able to demonstrate the change in the trajectory
of 1H MRS metabolite ratios with respect to the actual time of
symptom onset during a longitudinal evaluation.
We utilized the flex-point model by using the multipoint 1H
MRS datasets to determine when the change in the trajectory
of 1H MRS metabolites occurred with respect to the time of
symptom onset. Flex-point models have been used to model
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Fig 2. Voxel location and representative 1H magnetic resonance spectra from a converter with MAPT mutation. Posterior cingulate voxel is
placed on a mid-sagittal 3-dimensional T1-weighted image (left). Example of 1H MRS for a converter with MAPT mutation at 2 years before
symptom onset (A) and 2 year after symptom onset (B). The spectra are scaled to the creatine (Cr) peak as indicated with the dotted red line.
During follow-up, the myoinositol (mI) peak is elevated from 2 years before symptom onset with mI/Cr ratio of .48 (A) to 2 years after symptom
onset with mI/Cr ratio of .57 (B). NAA = N-acetylaspartate.
Table 2. Annual Change of Metabolite Ratios on Flex Point Models in Converters with MAPT Mutations
NAA/Cr mI/Cr NAA/mI
Estimates (95% CI) Estimates (95% CI) Estimates (95% CI)
Intercept 1.66 (1.60, 1.72)*** .49 (.46, .53)*** 3.37 (3.14, 3.62)***
Overall slope −.0003 (−.01, .01) −.007 (−.01, −.002)* .04 (.003, .08)*
Slope modifier after the flex point −.02 (−0.04, 0.006) .02 (.006, .03)* −.10 (−.18, −.02)*
Flex point dummy variable −.03 (−.08, .03) .04 (.01, .07)** −.30 (−.50, −.10)**
This flex point was estimated in the models using a dummy variable to shift the estimated line with the second slope up or down, thereby moving the flex point left or
right. The specific coding in our models estimated a slope over the entire time, and then a modifier to the slope after the flex point. The mixed models used random
intercepts to account for within-subject repeated measures correlations nested in within-family correlations. *P < .05, **P < .01, ***P < .001; CI = confidence interval;
Abbreviations: NAA = N-acetylaspartate; Cr = creatine; mI = myo-inositol.
atrophy rates in preclinical sporadic and familiar Alzheimer’s
disease.15,16 However, no prior studies have used flex-point
models in MAPT mutation carriers, making it difficult to com-
pare estimates. Our findings suggest that 1H MRS is a useful
biomarker for tracking of disease progression starting from the
asymptomatic stage.
In agreement with earlier cross-sectional 1H MRS studies in
asymptomatic MAPT mutation carriers,3 converters with MAPT
mutations had increasing mI/Cr ratio in posterior cingulate
voxel prior to symptom onset that continued after the age of
symptom onset. MI is present in glial cells17 and thought to
be related with glial proliferation and astrocytic and microglial
activation.18,19 Elevated mI was reported in both symptomatic
and asymptomaticMAPTmutation carriers in the posterior cin-
gulate voxel.3 Elevated mI is also a common feature of MCI
and mild AD even with normal NAA/Cr20–23 and associated
with higher amyloid-β burden in both cognitively unimpaired
individuals24,25 and those with preclinical AD.26 The posterior
cingulate voxel metabolite alterations starting from the asymp-
tomatic stage is characterized by increasing presumed glia
marker mI/Cr, followed by decreased NAA/Cr later, may sug-
gest a period of reactive astrocytosis inMAPTmutation carriers.
In the current study, decreasing NAA/mI ratios in con-
verters with MAPT mutation was mainly driven by increasing
mI/Cr ratios, since the slope of the change in neuronal marker
NAA/Cr ratios was not different from zero and did not have a
“flex-point” during the follow-up time window. A similar profile
characterized by elevated mI/Cr ratio without NAA/Cr ratio
change, are reported not only in asymptomaticMAPTmutation
carriers, but also in presymptomatic carriers of the amyloid pre-
cursor protein (APP) or presenilin 1 (PS1),27 indicating elevation
in mI/Cr precedes a decrease in NAA/Cr in posterior cingulate
voxel during the progression of neurodegenerative dementia.
The similar pattern of metabolite abnormalities between the
MAPTmutation carriers and presymptomatic AD with PS1 and
APPmutations suggest that the 1HMRS changes from posterior
cingulate voxel may be early markers of the neurodegenerative
pathology in familial neurodegenerative dementias with pro-
teinopathies caused by a variety of different mutations.3 How-
ever, we have recently demonstrated that the neuronal marker
NAA/Cr28–30 from media frontal lobe voxel is decreased in
asymptomatic MAPT mutation carriers,31 suggesting 1H MRS
metabolite alterations may vary by region. Frontal lobes are
one of the earliest brain regions involved with neurodegener-
ation and cortical atrophy in MAPT mutation carriers.32 The
limbic pathways are involved as MAPT mutation carriers be-
come symptomatic.33,34
A strength of our study was that the serial 1H MRS scans
were collected over 10 years, which made the tracking of the
disease progression from asymptomatic to symptomatic disease
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possible. However, the relatively small number of converters
was still a limitation. Further assessment in a larger cohort could
clarify whether our results are generalizable. Furthermore, data
collected from the other brain regions such as the frontal lobes
may provide further information on the regional distribution
of neurodegenerative pathology, which may be present in the
frontal lobes earlier than the posterior cingulate gyrus. In ad-
dition, using the absolute quantification of metabolite concen-
trations rather than the metabolite ratios from 1H MRS data
and utilizing more advanced acquisition methods to quantify
metabolites such as glutamine may provide more information
about the mechanisms of metabolite changes associated with
MAPT mutations in the future.
In conclusion, our data indicate an accelerated change in
the 1H MRS metabolite ratios in MAPT mutation carriers as
they transition from asymptomatic to symptomatic disease. Our
findings support the utilization of longitudinal 1H MRS as a
potential biomarker for monitoring the neurodegenerative dis-
ease progression in MAPT mutation carriers starting from the
asymptomatic stage, which may have implications for estimat-
ing efficacy in future disease-modifying trials.
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